KR20190075078A - ALK4:ActRIIB 이형다량체 및 이의 용도 - Google Patents
ALK4:ActRIIB 이형다량체 및 이의 용도 Download PDFInfo
- Publication number
- KR20190075078A KR20190075078A KR1020197012900A KR20197012900A KR20190075078A KR 20190075078 A KR20190075078 A KR 20190075078A KR 1020197012900 A KR1020197012900 A KR 1020197012900A KR 20197012900 A KR20197012900 A KR 20197012900A KR 20190075078 A KR20190075078 A KR 20190075078A
- Authority
- KR
- South Korea
- Prior art keywords
- seq
- position corresponding
- alk4
- actriib
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 title claims abstract description 342
- 102100034134 Activin receptor type-1B Human genes 0.000 title claims abstract description 311
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 title claims abstract description 167
- 229920001184 polypeptide Polymers 0.000 claims abstract description 67
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 67
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 67
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 42
- 210000003734 kidney Anatomy 0.000 claims abstract description 13
- 210000003205 muscle Anatomy 0.000 claims abstract description 9
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 8
- 206010028980 Neoplasm Diseases 0.000 claims abstract 5
- 201000011510 cancer Diseases 0.000 claims abstract 2
- 230000002503 metabolic effect Effects 0.000 claims abstract 2
- 108020001507 fusion proteins Proteins 0.000 claims description 524
- 102000037865 fusion proteins Human genes 0.000 claims description 524
- 238000006467 substitution reaction Methods 0.000 claims description 512
- 235000001014 amino acid Nutrition 0.000 claims description 504
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 397
- 229940024606 amino acid Drugs 0.000 claims description 287
- 150000001413 amino acids Chemical class 0.000 claims description 276
- 238000000034 method Methods 0.000 claims description 163
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 142
- 235000018417 cysteine Nutrition 0.000 claims description 142
- 239000000833 heterodimer Substances 0.000 claims description 134
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 101
- 235000013922 glutamic acid Nutrition 0.000 claims description 101
- 239000004220 glutamic acid Substances 0.000 claims description 101
- 239000004475 Arginine Substances 0.000 claims description 93
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 93
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 93
- 235000003704 aspartic acid Nutrition 0.000 claims description 93
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 93
- 235000004279 alanine Nutrition 0.000 claims description 82
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 80
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 76
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 73
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 65
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 64
- 239000004474 valine Substances 0.000 claims description 64
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical group NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 61
- 239000004472 Lysine Chemical group 0.000 claims description 61
- 230000002378 acidificating effect Effects 0.000 claims description 61
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Chemical group OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 61
- 230000004048 modification Effects 0.000 claims description 61
- 238000012986 modification Methods 0.000 claims description 61
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 59
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 57
- 150000007523 nucleic acids Chemical class 0.000 claims description 56
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 52
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 48
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 48
- 208000017169 kidney disease Diseases 0.000 claims description 45
- 102000039446 nucleic acids Human genes 0.000 claims description 45
- 108020004707 nucleic acids Proteins 0.000 claims description 45
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 44
- 210000004027 cell Anatomy 0.000 claims description 38
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 35
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 31
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 30
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 29
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 28
- 230000011664 signaling Effects 0.000 claims description 28
- 208000035475 disorder Diseases 0.000 claims description 25
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 25
- 206010016654 Fibrosis Diseases 0.000 claims description 23
- 238000000423 cell based assay Methods 0.000 claims description 23
- 230000004761 fibrosis Effects 0.000 claims description 23
- 125000000539 amino acid group Chemical group 0.000 claims description 22
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 21
- 239000003446 ligand Substances 0.000 claims description 20
- 201000008383 nephritis Diseases 0.000 claims description 18
- 102000040430 polynucleotide Human genes 0.000 claims description 18
- 108091033319 polynucleotide Proteins 0.000 claims description 18
- 239000002157 polynucleotide Substances 0.000 claims description 18
- 230000001154 acute effect Effects 0.000 claims description 17
- 208000020832 chronic kidney disease Diseases 0.000 claims description 17
- 230000004927 fusion Effects 0.000 claims description 17
- 239000000710 homodimer Substances 0.000 claims description 17
- 108091006020 Fc-tagged proteins Proteins 0.000 claims description 15
- 201000000585 muscular atrophy Diseases 0.000 claims description 15
- 201000001320 Atherosclerosis Diseases 0.000 claims description 14
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 claims description 14
- 101000893585 Homo sapiens Growth/differentiation factor 2 Proteins 0.000 claims description 14
- 108060003951 Immunoglobulin Proteins 0.000 claims description 14
- 102000018358 immunoglobulin Human genes 0.000 claims description 14
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 claims description 13
- 101000695367 Homo sapiens Bone morphogenetic protein 10 Proteins 0.000 claims description 13
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 13
- 239000003112 inhibitor Substances 0.000 claims description 12
- 239000008177 pharmaceutical agent Substances 0.000 claims description 12
- 102100035364 Growth/differentiation factor 3 Human genes 0.000 claims description 11
- 101001023986 Homo sapiens Growth/differentiation factor 3 Proteins 0.000 claims description 11
- 206010020772 Hypertension Diseases 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 11
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims description 10
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 claims description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims description 10
- 230000014509 gene expression Effects 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- 101710196692 Actin A Proteins 0.000 claims description 8
- 108700028369 Alleles Proteins 0.000 claims description 8
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 8
- -1 arginine (R) Chemical class 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 230000007935 neutral effect Effects 0.000 claims description 8
- 208000011580 syndromic disease Diseases 0.000 claims description 8
- 206010028289 Muscle atrophy Diseases 0.000 claims description 7
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 7
- 229960003067 cystine Drugs 0.000 claims description 7
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000020763 muscle atrophy Effects 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- 208000030761 polycystic kidney disease Diseases 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims description 5
- 101000899390 Homo sapiens Bone morphogenetic protein 6 Proteins 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 206010061989 glomerulosclerosis Diseases 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 206010039710 Scleroderma Diseases 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- 230000006735 deficit Effects 0.000 claims description 4
- 230000001037 epileptic effect Effects 0.000 claims description 4
- 201000001421 hyperglycemia Diseases 0.000 claims description 4
- 230000002458 infectious effect Effects 0.000 claims description 4
- 231100000417 nephrotoxicity Toxicity 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- 201000002793 renal fibrosis Diseases 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 3
- 208000037157 Azotemia Diseases 0.000 claims description 3
- 206010059517 Bacterial pyelonephritis Diseases 0.000 claims description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 3
- 108010036949 Cyclosporine Proteins 0.000 claims description 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 3
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 3
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims description 3
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 3
- 206010023439 Kidney transplant rejection Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010028851 Necrosis Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 3
- 208000033626 Renal failure acute Diseases 0.000 claims description 3
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 claims description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 3
- 201000011040 acute kidney failure Diseases 0.000 claims description 3
- 208000012998 acute renal failure Diseases 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 3
- 229960001265 ciclosporin Drugs 0.000 claims description 3
- 239000013078 crystal Substances 0.000 claims description 3
- 229930182912 cyclosporin Natural products 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 201000008319 inclusion body myositis Diseases 0.000 claims description 3
- 201000006334 interstitial nephritis Diseases 0.000 claims description 3
- 201000006370 kidney failure Diseases 0.000 claims description 3
- 150000002632 lipids Chemical group 0.000 claims description 3
- 206010028537 myelofibrosis Diseases 0.000 claims description 3
- 230000017074 necrotic cell death Effects 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 230000003389 potentiating effect Effects 0.000 claims description 3
- 208000009852 uremia Diseases 0.000 claims description 3
- 239000013598 vector Substances 0.000 claims description 3
- 230000004584 weight gain Effects 0.000 claims description 3
- 235000019786 weight gain Nutrition 0.000 claims description 3
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 claims description 2
- 108010059616 Activins Proteins 0.000 claims description 2
- 208000024985 Alport syndrome Diseases 0.000 claims description 2
- 206010003226 Arteriovenous fistula Diseases 0.000 claims description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 2
- 206010006895 Cachexia Diseases 0.000 claims description 2
- 229940122739 Calcineurin inhibitor Drugs 0.000 claims description 2
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 claims description 2
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 claims description 2
- 208000029147 Collagen-vascular disease Diseases 0.000 claims description 2
- 206010063044 Ectopic kidney Diseases 0.000 claims description 2
- 206010014666 Endocarditis bacterial Diseases 0.000 claims description 2
- 208000004929 Facial Paralysis Diseases 0.000 claims description 2
- 208000002682 Hyperkalemia Diseases 0.000 claims description 2
- 206010021263 IgA nephropathy Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 102100026818 Inhibin beta E chain Human genes 0.000 claims description 2
- 206010069384 Ischaemic nephropathy Diseases 0.000 claims description 2
- 208000000913 Kidney Calculi Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 2
- 206010058116 Nephrogenic anaemia Diseases 0.000 claims description 2
- 206010029148 Nephrolithiasis Diseases 0.000 claims description 2
- 206010029155 Nephropathy toxic Diseases 0.000 claims description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 2
- 208000004531 Renal Artery Obstruction Diseases 0.000 claims description 2
- 206010038378 Renal artery stenosis Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010063897 Renal ischaemia Diseases 0.000 claims description 2
- 206010038548 Renal vein thrombosis Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 206010039424 Salivary hypersecretion Diseases 0.000 claims description 2
- 208000008630 Sialorrhea Diseases 0.000 claims description 2
- 208000036826 VIIth nerve paralysis Diseases 0.000 claims description 2
- 239000000488 activin Substances 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 208000007502 anemia Diseases 0.000 claims description 2
- 208000009361 bacterial endocarditis Diseases 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- 230000007423 decrease Effects 0.000 claims description 2
- 230000008021 deposition Effects 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 208000002296 eclampsia Diseases 0.000 claims description 2
- 201000000523 end stage renal failure Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 208000003215 hereditary nephritis Diseases 0.000 claims description 2
- 201000007119 infective endocarditis Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 230000037257 muscle growth Effects 0.000 claims description 2
- 230000007694 nephrotoxicity Effects 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 230000008085 renal dysfunction Effects 0.000 claims description 2
- 231100001028 renal lesion Toxicity 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 208000019553 vascular disease Diseases 0.000 claims description 2
- 108091026890 Coding region Proteins 0.000 claims 6
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims 6
- 208000034189 Sclerosis Diseases 0.000 claims 6
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 5
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 4
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims 4
- 208000010706 fatty liver disease Diseases 0.000 claims 4
- 238000009168 stem cell therapy Methods 0.000 claims 4
- 238000009580 stem-cell therapy Methods 0.000 claims 4
- 206010003210 Arteriosclerosis Diseases 0.000 claims 3
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 3
- 206010035664 Pneumonia Diseases 0.000 claims 3
- 206010047115 Vasculitis Diseases 0.000 claims 3
- 238000001415 gene therapy Methods 0.000 claims 3
- 238000000554 physical therapy Methods 0.000 claims 3
- 201000000306 sarcoidosis Diseases 0.000 claims 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- 239000002083 C09CA01 - Losartan Substances 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 206010014664 Endocardial fibrosis Diseases 0.000 claims 2
- 206010019668 Hepatic fibrosis Diseases 0.000 claims 2
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 2
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 206010056997 Impaired fasting glucose Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010065973 Iron Overload Diseases 0.000 claims 2
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 2
- 208000018839 Wilson disease Diseases 0.000 claims 2
- 108010023079 activin B Proteins 0.000 claims 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims 2
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 235000006708 antioxidants Nutrition 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 229960001334 corticosteroids Drugs 0.000 claims 2
- 229960003624 creatine Drugs 0.000 claims 2
- 239000006046 creatine Substances 0.000 claims 2
- 230000037213 diet Effects 0.000 claims 2
- 235000005911 diet Nutrition 0.000 claims 2
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 claims 2
- 229950009041 edaravone Drugs 0.000 claims 2
- 208000007345 glycogen storage disease Diseases 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 229960004773 losartan Drugs 0.000 claims 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims 2
- 230000002107 myocardial effect Effects 0.000 claims 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 2
- 229960004618 prednisone Drugs 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 229960004181 riluzole Drugs 0.000 claims 2
- 229960002052 salbutamol Drugs 0.000 claims 2
- 238000002630 speech therapy Methods 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims 2
- 201000008827 tuberculosis Diseases 0.000 claims 2
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 claims 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 208000010444 Acidosis Diseases 0.000 claims 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims 1
- 206010001939 Aminoaciduria Diseases 0.000 claims 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 206010063659 Aversion Diseases 0.000 claims 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims 1
- 206010004637 Bile duct stone Diseases 0.000 claims 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 201000009331 Choledocholithiasis Diseases 0.000 claims 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims 1
- 201000006306 Cor pulmonale Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000005189 Embolism Diseases 0.000 claims 1
- 108010061435 Enalapril Proteins 0.000 claims 1
- 208000024720 Fabry Disease Diseases 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 claims 1
- 102000009123 Fibrin Human genes 0.000 claims 1
- 108010073385 Fibrin Proteins 0.000 claims 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 102000029746 Histidine-tRNA Ligase Human genes 0.000 claims 1
- 101710177011 Histidine-tRNA ligase, cytoplasmic Proteins 0.000 claims 1
- 102000002265 Human Growth Hormone Human genes 0.000 claims 1
- 108010000521 Human Growth Hormone Proteins 0.000 claims 1
- 239000000854 Human Growth Hormone Substances 0.000 claims 1
- 206010020524 Hydronephrosis Diseases 0.000 claims 1
- 208000037147 Hypercalcaemia Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000003623 Hypoalbuminemia Diseases 0.000 claims 1
- 208000006083 Hypokinesia Diseases 0.000 claims 1
- 208000021330 IgG4-related disease Diseases 0.000 claims 1
- 208000024934 IgG4-related mediastinitis Diseases 0.000 claims 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims 1
- 208000037142 IgG4-related systemic disease Diseases 0.000 claims 1
- 208000004187 Immunoglobulin G4-Related Disease Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 102000004895 Lipoproteins Human genes 0.000 claims 1
- 108090001030 Lipoproteins Proteins 0.000 claims 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims 1
- 208000002805 Mediastinal fibrosis Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010027525 Microalbuminuria Diseases 0.000 claims 1
- 206010028629 Myoglobinuria Diseases 0.000 claims 1
- 208000013901 Nephropathies and tubular disease Diseases 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 101710096715 Probable histidine-tRNA ligase, cytoplasmic Proteins 0.000 claims 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 claims 1
- 206010060872 Transplant failure Diseases 0.000 claims 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims 1
- 102000005630 Urocortins Human genes 0.000 claims 1
- 108010059705 Urocortins Proteins 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000007950 acidosis Effects 0.000 claims 1
- 208000026545 acidosis disease Diseases 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 229960002478 aldosterone Drugs 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 230000001088 anti-asthma Effects 0.000 claims 1
- 239000000924 antiasthmatic agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 229960004530 benazepril Drugs 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 210000000941 bile Anatomy 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 229960000932 candesartan Drugs 0.000 claims 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims 1
- 239000002371 cardiac agent Substances 0.000 claims 1
- 229960004203 carnitine Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 235000017471 coenzyme Q10 Nutrition 0.000 claims 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims 1
- 229940110767 coenzyme Q10 Drugs 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims 1
- 229960004166 diltiazem Drugs 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 229960000873 enalapril Drugs 0.000 claims 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 1
- 229950003499 fibrin Drugs 0.000 claims 1
- 235000021323 fish oil Nutrition 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 208000018914 glucose metabolism disease Diseases 0.000 claims 1
- 235000020688 green tea extract Nutrition 0.000 claims 1
- 229940094952 green tea extract Drugs 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000006750 hematuria Diseases 0.000 claims 1
- 201000001505 hemoglobinuria Diseases 0.000 claims 1
- 238000002657 hormone replacement therapy Methods 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 230000000148 hypercalcaemia Effects 0.000 claims 1
- 208000030915 hypercalcemia disease Diseases 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 1
- 230000001631 hypertensive effect Effects 0.000 claims 1
- 230000003483 hypokinetic effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229960002198 irbesartan Drugs 0.000 claims 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 239000010977 jade Substances 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 1
- 208000009242 medullary sponge kidney Diseases 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims 1
- 229940014456 mycophenolate Drugs 0.000 claims 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 201000009925 nephrosclerosis Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 239000002796 non-dihydropyridine calcium channel blocker Substances 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000000557 podocyte Anatomy 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 208000003476 primary myelofibrosis Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 201000008158 rapidly progressive glomerulonephritis Diseases 0.000 claims 1
- 206010038464 renal hypertension Diseases 0.000 claims 1
- 210000005084 renal tissue Anatomy 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 229960005187 telmisartan Drugs 0.000 claims 1
- 229960003604 testosterone Drugs 0.000 claims 1
- 208000037816 tissue injury Diseases 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 229940116269 uric acid Drugs 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 239000000777 urocortin Substances 0.000 claims 1
- ZEBBPGHOLWPSGI-KPLDDXDLSA-N urocortin ii Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CS)C(N)=O)CC1=CN=CN1 ZEBBPGHOLWPSGI-KPLDDXDLSA-N 0.000 claims 1
- 229960004699 valsartan Drugs 0.000 claims 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 1
- 230000006492 vascular dysfunction Effects 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 abstract description 4
- 230000009753 muscle formation Effects 0.000 abstract description 2
- 210000000845 cartilage Anatomy 0.000 abstract 1
- 210000000750 endocrine system Anatomy 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 230000011164 ossification Effects 0.000 abstract 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 27
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 18
- 102000007469 Actins Human genes 0.000 description 16
- 108010085238 Actins Proteins 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 13
- 230000027455 binding Effects 0.000 description 12
- 230000003993 interaction Effects 0.000 description 11
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 10
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 5
- 102000043168 TGF-beta family Human genes 0.000 description 5
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108091085018 TGF-beta family Proteins 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 102000007474 Multiprotein Complexes Human genes 0.000 description 3
- 108010085220 Multiprotein Complexes Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 208000006575 hypertriglyceridemia Diseases 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 2
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 2
- 208000024940 Dent disease Diseases 0.000 description 2
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 2
- 206010018378 Glomerulonephritis rapidly progressive Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 2
- 108050009527 Hypoxia-inducible factor-1 alpha Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010062237 Renal impairment Diseases 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000001195 anabolic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001925 catabolic effect Effects 0.000 description 2
- 201000005637 crescentic glomerulonephritis Diseases 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 108020001756 ligand binding domains Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000002887 multiple sequence alignment Methods 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101710196690 Actin B Proteins 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 102100031168 CCN family member 2 Human genes 0.000 description 1
- 101150008656 COL1A1 gene Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010063209 Chronic allograft nephropathy Diseases 0.000 description 1
- 201000000057 Coronary Stenosis Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 201000001200 Crouzon syndrome-acanthosis nigricans syndrome Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 description 1
- 206010018374 Glomerulonephritis minimal lesion Diseases 0.000 description 1
- 208000032003 Glycogen storage disease due to glucose-6-phosphatase deficiency Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 102100034471 H(+)/Cl(-) exchange transporter 5 Human genes 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 102000013519 Lipocalin-2 Human genes 0.000 description 1
- 108010051335 Lipocalin-2 Proteins 0.000 description 1
- 208000004883 Lipoid Nephrosis Diseases 0.000 description 1
- 101710091439 Major capsid protein 1 Proteins 0.000 description 1
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 description 1
- 102100025744 Mothers against decapentaplegic homolog 1 Human genes 0.000 description 1
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 1
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 1
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 1
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 1
- 102100030610 Mothers against decapentaplegic homolog 5 Human genes 0.000 description 1
- 101710143113 Mothers against decapentaplegic homolog 5 Proteins 0.000 description 1
- 108010056852 Myostatin Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 206010038481 Renal necrosis Diseases 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 101700032040 SMAD1 Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000022401 dense deposit disease Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000009786 epithelial differentiation Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 1
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 201000004541 glycogen storage disease I Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 208000031424 hyperprolactinemia Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 231100000855 membranous nephropathy Toxicity 0.000 description 1
- 201000008265 mesangial proliferative glomerulonephritis Diseases 0.000 description 1
- 206010063344 microscopic polyangiitis Diseases 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 208000038001 non-diabetic kidney disease Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 201000008171 proliferative glomerulonephritis Diseases 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000007261 regionalization Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404727P | 2016-10-05 | 2016-10-05 | |
| US62/404,727 | 2016-10-05 | ||
| US201762510417P | 2017-05-24 | 2017-05-24 | |
| US62/510,417 | 2017-05-24 | ||
| PCT/US2017/055426 WO2018067879A1 (en) | 2016-10-05 | 2017-10-05 | Alk4:actriib heteromultimers and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20190075078A true KR20190075078A (ko) | 2019-06-28 |
Family
ID=61831282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197012900A Ceased KR20190075078A (ko) | 2016-10-05 | 2017-10-05 | ALK4:ActRIIB 이형다량체 및 이의 용도 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10934532B2 (https=) |
| EP (1) | EP3522913A4 (https=) |
| JP (2) | JP7219705B2 (https=) |
| KR (1) | KR20190075078A (https=) |
| CN (1) | CN110678195A (https=) |
| AU (1) | AU2017338921A1 (https=) |
| BR (1) | BR112019006993A2 (https=) |
| CA (1) | CA3039573A1 (https=) |
| MA (1) | MA46472A (https=) |
| TW (1) | TW201813978A (https=) |
| WO (1) | WO2018067879A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107849114B (zh) | 2015-04-06 | 2021-08-20 | 阿塞勒隆制药公司 | 单臂i型和ii型受体融合蛋白和其用途 |
| MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| US10227392B2 (en) | 2015-04-06 | 2019-03-12 | Acceleron Pharma Inc. | ALK7:ActRIIB heteromultimers and uses thereof |
| WO2017177013A1 (en) | 2016-04-06 | 2017-10-12 | Acceleron Pharma Inc. | Alk7 antagonists and uses thereof |
| BR112019006993A2 (pt) | 2016-10-05 | 2019-09-03 | Acceleron Pharma Inc | heteromultímeros de alk4:actriib e usos dos mesmos |
| US11440949B2 (en) | 2016-10-05 | 2022-09-13 | Acceleron Pharma Inc. | TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof |
| JP7280182B2 (ja) | 2016-10-05 | 2023-05-23 | アクセルロン ファーマ インコーポレイテッド | バリアントＡｃｔＲＩＩＢタンパク質およびその使用 |
| CA3099325A1 (en) | 2018-05-03 | 2019-11-07 | Acceleron Pharma Inc. | Novel binders of tgf.beta.-superfamily ligands and uses thereof |
| CN111269943B (zh) * | 2019-08-10 | 2023-01-06 | 湖南文理学院 | 一种通过基因敲除技术增加斑马鱼生长速度的方法 |
| EP4073101A4 (en) * | 2019-12-10 | 2024-01-10 | Acceleron Pharma Inc. | SINGLE-ARM ACTRIIA AND ACTRIIB HETEROMULTIMERS AND METHOD FOR TREATING PULMONARY HYPERTENSION |
| EP4100431A4 (en) * | 2020-02-03 | 2024-10-16 | Acceleron Pharma Inc. | Variant actriib proteins and uses thereof |
| WO2021183819A1 (en) * | 2020-03-13 | 2021-09-16 | Acceleron Pharma Inc. | Single-arm actriia and actriib heteromultimers and methods for treating renal diseases or conditions |
| WO2021189010A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| IL296394A (en) | 2020-03-20 | 2022-11-01 | Keros Therapeutics Inc | Type ii activin receptor chimeras and methods of using them |
| JP2023534127A (ja) * | 2020-06-17 | 2023-08-08 | アクセルロン ファーマ インコーポレイテッド | ＡｃｔＲＩＩ－ＡＬＫ４アンタゴニストおよび心不全を処置する方法 |
| US20220288226A1 (en) * | 2020-08-27 | 2022-09-15 | Enosi Life Sciences Corp. | Methods and compositions to treat autoimmune diseases and cancer |
| WO2022192420A2 (en) * | 2021-03-10 | 2022-09-15 | Acceleron Pharma Inc. | Actrii proteins and uses thereof |
| US20250064952A1 (en) * | 2021-03-10 | 2025-02-27 | Acceleron Pharma Inc. | Actrii-alk4 antagonists and methods of treating heart failure |
| JP2024511315A (ja) * | 2021-03-10 | 2024-03-13 | アクセルロン ファーマ インコーポレイテッド | Ａｃｔｒｉｉ－ａｌｋ４アンタゴニスト及び心不全の治療方法 |
| US20250041385A1 (en) * | 2021-12-10 | 2025-02-06 | Biogen Ma Inc. | Modified actrii proteins and methods of use thereof |
| WO2024238950A1 (en) * | 2023-05-18 | 2024-11-21 | Keros Therapeutics, Inc. | Methods of using activin receptor type ii variants |
| WO2025183964A1 (en) * | 2024-02-27 | 2025-09-04 | Alivegen Usa, Inc | Methods of treating myostatin-related or activin a-related disorders using novel hybrid actriib ligand trap proteins |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| US7592428B1 (en) | 1992-11-17 | 2009-09-22 | Ludwig Institute For Cancer Research | Antibodies which bind specifically to activin receptor like kinases |
| KR950704485A (ko) | 1992-11-17 | 1995-11-20 | 로이드 제이. 오울드·에드워드 에이, 맥더모 2세 | 액티빈 리셉터-유사 키나제, 세린 트레오닌 키나제 도메인을 갖는 단백질 및 이들의 용도(activin receptor-like kinases, proteins having serine threonine kinase domains and their use) |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| AU772694B2 (en) | 1999-01-21 | 2004-05-06 | Metamorphix International, Inc. | Growth differentiation factor inhibitors and uses therefor |
| GB0209896D0 (en) * | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
| US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| CA2539116C (en) | 2003-09-15 | 2014-11-18 | Research Development Foundation | Cripto antagonism of activin and tgf-b signaling |
| US7833971B2 (en) | 2006-12-08 | 2010-11-16 | Acceleron Pharma Inc. | Uses of cerberus, coco and derivatives thereof |
| EP1771470B1 (en) | 2004-07-23 | 2013-06-26 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
| KR20190006086A (ko) | 2005-11-23 | 2019-01-16 | 악셀레론 파마 인코포레이티드 | 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도 |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| EP2108017A2 (en) | 2007-01-30 | 2009-10-14 | Biogen Idec MA, Inc. | Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists |
| TWI782836B (zh) | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| TWI573802B (zh) | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| ES2449753T3 (es) | 2007-03-19 | 2014-03-21 | National Research Council Of Canada | Proteínas de fusión que comprenden dos dominios de unión tgf-beta |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| SMT202300222T1 (it) | 2008-08-14 | 2023-09-06 | Acceleron Pharma Inc | Trappole di gdf |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| EP2326670A4 (en) | 2008-09-17 | 2014-04-16 | Nat Res Council Canada | HETERO MULTIVALENT BINDING AGENT FOR ELEMENTS OF THE TGF-BETA SUPERFAMILY |
| SG10201703067QA (en) | 2008-11-26 | 2017-05-30 | Amgen Inc | Variants Of Activin IIB Receptor Polypeptides And Uses Thereof |
| US8138142B2 (en) | 2009-01-13 | 2012-03-20 | Acceleron Pharma Inc. | Methods for increasing adiponectin in a patient in need thereof |
| EP2440577A4 (en) | 2009-06-12 | 2013-01-23 | Acceleron Pharma Inc | SHORTEN ACTRIIB FC FUSION PROTEINS |
| KR20120108967A (ko) | 2009-09-16 | 2012-10-05 | 제넨테크, 인크. | 코일드 코일 및/또는 테더 함유 단백질 복합체 및 그의 용도 |
| FR2951408B1 (fr) | 2009-10-15 | 2012-01-13 | Renault Sa | Cadre moteur pour moteur electrique de vehicule automobile |
| US8999343B2 (en) | 2010-08-16 | 2015-04-07 | Amgen Inc. | Antibodies that bind myostatin, compositions and methods |
| WO2012088302A2 (en) | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Half immunoglobulin binding proteins and uses thereof |
| CN102850458B (zh) | 2011-06-28 | 2014-10-01 | 华博生物医药技术（上海）有限公司 | 新型重组双功能融合蛋白及其制法和用途 |
| WO2013055809A1 (en) | 2011-10-10 | 2013-04-18 | Xencor, Inc. | A method for purifying antibodies |
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| PL2831105T3 (pl) | 2012-03-28 | 2018-01-31 | Univ Texas | Fuzje receptora tgf typu ii - typu iii |
| JP6631865B2 (ja) | 2014-08-11 | 2020-01-15 | 日本化薬株式会社 | ＴＧＦβ阻害機能を持つキメラタンパク質 |
| WO2016090035A2 (en) | 2014-12-02 | 2016-06-09 | La Jolla Institute For Allergy And Immunology | Modulators of activin and methods for modulating immune responses and t follicular helper cells |
| AU2016238254B2 (en) * | 2015-03-26 | 2022-05-05 | Acceleron Pharma Inc. | Follistatin-related fusion proteins and uses thereof |
| CN107849114B (zh) | 2015-04-06 | 2021-08-20 | 阿塞勒隆制药公司 | 单臂i型和ii型受体融合蛋白和其用途 |
| US10227392B2 (en) | 2015-04-06 | 2019-03-12 | Acceleron Pharma Inc. | ALK7:ActRIIB heteromultimers and uses thereof |
| MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| PT3286206T (pt) | 2015-04-22 | 2021-04-01 | Biogen Ma Inc | Novas proteínas híbridas bloqueadoras de ligando actriib para tratar doenças de desgaste muscular |
| WO2016205370A1 (en) | 2015-06-15 | 2016-12-22 | Santa Maria Biotherapeutics, Inc. | Methods of using activin receptor iib-based proteins |
| US20200231652A1 (en) | 2015-08-31 | 2020-07-23 | National Research Council Of Canada | Tgf-b-receptor ectodomain fusion molecules and uses thereof |
| AU2017222526A1 (en) | 2016-02-22 | 2018-08-23 | Acceleron Pharma Inc. | ActRII antagonists for use in increasing immune activity |
| WO2017177013A1 (en) | 2016-04-06 | 2017-10-12 | Acceleron Pharma Inc. | Alk7 antagonists and uses thereof |
| AU2017293778B2 (en) | 2016-07-07 | 2022-03-24 | Acceleron Pharma Inc. | TGF-beta superfamily heteromultimers and uses thereof |
| WO2018009732A1 (en) | 2016-07-08 | 2018-01-11 | Regeneron Pharmaceuticals, Inc. | Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension |
| BR112019006993A2 (pt) | 2016-10-05 | 2019-09-03 | Acceleron Pharma Inc | heteromultímeros de alk4:actriib e usos dos mesmos |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
-
2017
- 2017-10-05 BR BR112019006993A patent/BR112019006993A2/pt not_active IP Right Cessation
- 2017-10-05 MA MA046472A patent/MA46472A/fr unknown
- 2017-10-05 TW TW106134359A patent/TW201813978A/zh unknown
- 2017-10-05 CA CA3039573A patent/CA3039573A1/en active Pending
- 2017-10-05 US US15/726,255 patent/US10934532B2/en active Active
- 2017-10-05 JP JP2019518299A patent/JP7219705B2/ja active Active
- 2017-10-05 AU AU2017338921A patent/AU2017338921A1/en not_active Abandoned
- 2017-10-05 EP EP17859224.2A patent/EP3522913A4/en active Pending
- 2017-10-05 KR KR1020197012900A patent/KR20190075078A/ko not_active Ceased
- 2017-10-05 CN CN201780075170.8A patent/CN110678195A/zh active Pending
- 2017-10-05 WO PCT/US2017/055426 patent/WO2018067879A1/en not_active Ceased
-
2020
- 2020-12-28 US US17/134,703 patent/US12054753B2/en active Active
-
2022
- 2022-09-30 JP JP2022157844A patent/JP2022177286A/ja active Pending
-
2024
- 2024-06-20 US US18/749,233 patent/US20250084388A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US10934532B2 (en) | 2021-03-02 |
| JP2022177286A (ja) | 2022-11-30 |
| CN110678195A (zh) | 2020-01-10 |
| CA3039573A1 (en) | 2018-04-12 |
| US20250084388A1 (en) | 2025-03-13 |
| EP3522913A4 (en) | 2020-10-28 |
| MA46472A (fr) | 2019-08-14 |
| JP7219705B2 (ja) | 2023-02-08 |
| US20180163187A1 (en) | 2018-06-14 |
| WO2018067879A1 (en) | 2018-04-12 |
| JP2019536438A (ja) | 2019-12-19 |
| TW201813978A (zh) | 2018-04-16 |
| EP3522913A1 (en) | 2019-08-14 |
| US20210363502A1 (en) | 2021-11-25 |
| US12054753B2 (en) | 2024-08-06 |
| AU2017338921A1 (en) | 2019-04-18 |
| BR112019006993A2 (pt) | 2019-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250084388A1 (en) | Alk4:actriib heteromultimers and uses thereof | |
| US12338273B2 (en) | Single-arm type I and type II receptor fusion proteins and uses thereof | |
| KR102761094B1 (ko) | 변이체 actriib 단백질 및 이의 용도 | |
| KR20180002659A (ko) | Tgf-베타 슈퍼패밀리 유형 i 및 유형 ii 수용체 이형다합체들과 이의 용도 | |
| KR20180002660A (ko) | ALK4:ActRIIB 이형다합체 및 이의 용도 | |
| AU2017338915B2 (en) | TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof | |
| AU2022201603A1 (en) | TGF-beta superfamily heteromultimers and uses thereof | |
| US20230183319A1 (en) | Variant actriib proteins and uses thereof | |
| US20230129812A1 (en) | Compositions and methods for treating pulmonary hypertension | |
| HK40064908A (en) | Single-arm type i and type ii receptor fusion proteins and uses thereof | |
| HK40061777A (en) | Single-arm type i and type ii receptor fusion proteins and uses thereof | |
| BR122024002253A2 (pt) | Polipeptídeo compreendendo sequência de aminoácidos de actriib, ácido nucleico compreendendo uma sequência que codifica o dito polipeptídeo, vetor compreendendo o dito ácido nucléico, célula compreendendo polipeptídeo, ácido nucleico ou vetor, usos terapêuticos do dito polipeptídeo e do dito ácido nucléico e métodos para produzir um polupeptídeo, uma proteína ou uma heteromultímera, piroteína e heteromultímera compreendendo um polipeptídeo actriib variante |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20190503 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20201005 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20220808 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20230629 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20220808 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |